SOURCE: Daxor Corp.

February 12, 2007 08:30 ET

Daxor Corporation Files Methods Patent for Blood Optimization Method

NEW YORK, NY -- (MARKET WIRE) -- February 12, 2007 -- Daxor Corporation (AMEX: DXR), a medical instrumentation and biotechnology company, today announced it has filed for a patent for its Blood Optimization Program.

The Company has developed a program which enables patients undergoing elective surgery to enter surgery with a normal amount of blood and to have additional blood of their own available during the operative and post-operative period. The methodology includes use of the Company's patented BVA-100 blood volume analyzer, which enables the total amount of blood in the human body to be measured with an accuracy of within 98%. The methodology also incorporates the use of blood stimulants such as Epoietin Alfa, which is manufactured by the Amgen Corporation, and the use of frozen blood bank technology.

Utilization of these techniques can significantly reduce the incidence of patients entering surgery in a blood depleted state. The standard tests used to detect anemia, such as hematocrit or hemoglobin, are only accurate if the patient has a normal blood volume. Many patients, however, have a decreased blood volume which masks the true extent of their anemia. Women normally have 18% fewer red blood cells than men of equal height and weight. They are, therefore, significantly more vulnerable to needing a transfusion and have a higher incidence of complications from transfusions.

Utilization of one's own blood avoids problems including infections which cannot be detected by the standard screening methods, as well as transfusion reactions which may occur because blood is never completely cross matched between a donor and a recipient. Another problem that studies have shown is that refrigerated blood, available for a maximum of 42 days, undergoes significant deterioration within 20 to 30 days. Frozen blood, which is thawed within 24 to 72 hours of actual use, shows minimal negative changes. Specially prepared frozen blood can be stored for up to 10 years.

A common method of obtaining blood within 1 to 4 weeks prior to its use usually does not permit enough time for the patient to replenish the lost blood. The Blood Optimization Program, because of its freezing technology, enables blood to be obtained well before surgery, with adequate time for the patient to replenish the donated blood. Individuals who are at potential risk for requiring surgery, such as patients with significant cardiac disease or orthopedic disabilities, can benefit from this type of program. Another group of patients who could benefit are patients with potential high risk pregnancies. At the present time the Company plans to license its methodology to various hospitals.

Daxor Corporation manufactures and markets the BVA-100, a semi-automated Blood Volume Analyzer. The BVA-100 is used in conjunction with Volumex, Daxor's single use diagnostic kit. For more information regarding Daxor Corporation's Blood Volume Analyzer BVA-100, visit Daxor's website

Contact Information

  • Contact Information:
    Stephen Feldschuh
    (Chief Operating Officer)
    Email Contact

    Diane Meegan
    (Investor Relations)
    Email Contact.